NEW YORK (360Dx) – Boston Scientific this week acquired privately held nVision Medical for an upfront cash payment of $150 million, and up to an additional $125 million if potential clinical and commercial milestones are met. nVision has developed a US Food and Drug Administration-cleared device to collect cells from fallopian tubes. The device may be developed into a technology for the earlier diagnosis of ovarian cancer, Boston Scientific said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.